<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05791656</url>
  </required_header>
  <id_info>
    <org_study_id>P07.001.09</org_study_id>
    <nct_id>NCT05791656</nct_id>
  </id_info>
  <brief_title>Interference Screw Mectascrew-C Postmarket Study</brief_title>
  <official_title>Composite Interference Screw in the Surgical Reconstruction of Knee Cruciate Ligaments: a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medacta International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medacta International SA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational prospective study with the aim to analyze the presence at 6 months of a&#xD;
      specific composite IS (Medacta Mectascrew C) in the reconstructive treatment of ruptured ACL&#xD;
      or PCL by means of an autograft or allograft.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational prospective study with the aim to determine the presence of the&#xD;
      composite IS (Mectascrew-C) at 6 months following ACL or PCL reconstruction.&#xD;
&#xD;
      Patients with an ACL or PCL tear scheduled for surgery at one of the EOC's hospitals will be&#xD;
      enrolled in the study, after the subscription of informed consent. The injured ligament will&#xD;
      be restored with an auto- or allograft that will be fixed with a composite IS (Mectascrew-C,&#xD;
      70% PLDLLA, 30% Î²-TCP, Medacta International SA).&#xD;
&#xD;
      The data will be collected from patient's medical histories (data about diagnosis, patients'&#xD;
      characteristics and surgery) and after operation, during the orthopaedic follow-up visits,&#xD;
      planned at 1, 3 and 6 months, in order to assess the functional outcomes (IKDC objective and&#xD;
      subjective) and the knee stability (ROM, Pivot Shift or Reverse Pivot Shift test, anterior or&#xD;
      posterior drawer test) of the patients.&#xD;
&#xD;
      The treated knee will be also evaluated radiologically with an MRI at 6 months to assess the&#xD;
      IS reabsorption. The results of this exam will be correlated to the pre-operative findings&#xD;
      and to the functional and clinical outcomes evaluated with the different forms&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2023</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interference screw presence</measure>
    <time_frame>6 months</time_frame>
    <description>via MRI imaging at 6 months after surgery, the presence of the Mectascrew-C will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mobility outcomes evaluation</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Assessment throught Range Of Motion of operated knee calculated as degree</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcomes evaluation</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Assessment throught IKCD score. a patient-completed tool, which contains sections on knee symptoms (7 items), function (2 items), and sports activities (2 items). Scores range from 0 points (lowest level of function or highest level of symptoms) to 100 points (highest level of function and lowest level of symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee stability evaluation of ACL intervention</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Pivot shift test. A positive test indicate an injury at ACL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACL integrity assessment</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Anterior drawer test. An anterior translation more than 6 mm indicate a positive test with injuried ACL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee stability evaluation of PCL intervention</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Reverse Pivot Shift test. In the presence of a posterolateral injury with the knee flexed, the tibia follows gravity and drops into posterolateral subluxation (positive Reverse Pivot Shift Test).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCL integrity assessment</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>Posterior drawer test. The test is considered positive if there is a lack of end feel or excessive posterior translation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device safety evaluation</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>collection of adverse event</description>
  </secondary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Anterior Cruciate Ligament Injuries</condition>
  <condition>Posterior Cruciate Ligament Tear</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mectascrew-C</intervention_name>
    <description>reconstruction of ACL or PCL rupture</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with an ACL or PCL rupture, and meeting the inclusion/exclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both sexes aged 16-60 yrs&#xD;
&#xD;
          -  Pre-operative MRI confirming the ACL or PCL rupture&#xD;
&#xD;
          -  Scheduled for surgical reconstruction of ACL or PCL&#xD;
&#xD;
          -  BMI&gt;18 and &lt;35 kg/m2&#xD;
&#xD;
          -  Ability to give informed consent by signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 16 or over 60 yrs&#xD;
&#xD;
          -  Degenerative osteopathies&#xD;
&#xD;
          -  Local bone tumors&#xD;
&#xD;
          -  Deformities of the bone, or general conditions of the bone, which preclude the&#xD;
             implantation in the opinion of a physician&#xD;
&#xD;
          -  Systemic diseases and metabolic disorders that may compromise the outcome of the&#xD;
             surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Candrian, Prof Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>EOC , Service of Orthopaedics and Traumatology, Lugano (Switzerland)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Bonacina, PhD</last_name>
    <phone>+41 91 696 60 60</phone>
    <email>bonacina@medacta.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>EOC, Service of Orthopaedics and Traumatology</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6962</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Sangiorgio, Dr</last_name>
      <email>Alessandro.Sangiorgio@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Candrian, Prof Dr Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 7, 2023</study_first_submitted>
  <study_first_submitted_qc>March 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2023</study_first_posted>
  <last_update_submitted>April 4, 2023</last_update_submitted>
  <last_update_submitted_qc>April 4, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anterior Cruciate Ligament Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

